4 Marijuana Stocks Bubbling with Excitement on Wednesday (2/13/19)

CORAL GABLES, FL / ACCESSWIRE / February 13, 2019 / The 2019 year has already managed to be a catalyst for growth for the marijuana stock market. We've seen a significant increase in stock prices for some of the larger companies in the industry. During this time, companies have returned to their pre-September numbers as the end of the last year was detrimental to values for the market. We've recently seen a push from lawmakers, across the aisle, for supportive legislation in favor of legalizing marijuana on a federal level. For the future of the industry to be secured, lawmakers need to press onward with passing this type of legislation, because, ultimately, this will allow companies in the sector to continue operating and developing novel products to distribute throughout the domestic cannabis market, rather than in a select few states. Nabis Holdings (INNPF) (NAB), Canopy Growth Corp (CGC) (WEED), GW Pharmaceuticals plc (GWPH), and CV Sciences Inc (CVSI) are four cannabis companies worth keeping on your radar.

Nabis Holdings (INNPF) (NAB) is a Canadian investment company determined to make strategic investments in a multitude of high-quality cash flowing assets across an array of businesses in the cannabis sector, primarily in U.S. limited license states. The Company plans to take its operations globally in the near future. Presently, Nabis works throughout the U.S. by identifying companies with high growth potential, where they can then gain a majority stake. The Company's core ideology is based around a framework designed to give the Company the opportunity to identify, and subsequently acquire majority-stake interests in companies across the broad spectrum of vertically integrated businesses, with a focus on strategic revenue generation, EBITDA and growth.

Nabis Holdings (INNPF) (NAB) announced last week that the Company has entered into a binding term sheet with Momentum Ideas Co to acquire certain assets used and marketed under the brand Bloombox, including the Bloombox Software and data platform. Nabis' acquisition of Bloombox will create a dominating presence in the growing U.S. cannabis market, featuring an integrated ecosystem of modern, next-generation technology.

Per the details of the agreement, the Bloombox team will work closely with Nabis Holdings (INNPF) (NAB), including Sam Gammon, the Company's inbound Chief Technology Officer following the closing of the Investment.

Shay Shnet, Chief Executive Officer and Director of Nabis Holdings (INNPF) (NAB), said, "Bloombox is a strategic investment for Nabis as it creates a very well established retail and supply chain ecosystem to be used and distributed across the Nabis' network of dispensaries across the United States," said Shay Shnet, CEO & Director of Nabis. "We look forward to working with the Bloombox team to further establish this retail cannabis software as the industry standard that we expect to be adopted by almost all cannabis retail locations, supply chain, & users."

For More Information On Nabis Holdings, Click Here

Canopy Growth Corp (CGC) (WEED) found itself dominating headlines this month after the Company announced at the tail-end of last week that it intends to increase its total investment in Canopy Rivers Inc by $30 million. The investment will be made through a private placement of subordinated voting shares in the capital of Canopy Rivers concurrent with Canopy Rivers bought deal offering of Subordinate Voting Shares for gross proceeds of approximately $55 million.

Following the announcement of their planned investment, Bruce Linton, Founder, and co-CEO of Canopy, stated that "By increasing Canopy Growth's investment in Canopy Rivers, we are demonstrating our interest in growing great companies, developing selective opportunities and delivering Canopy's shareholders more growth."

For More Information On Canopy Growth Corp, Click Here

GW Pharmaceuticals plc (GWPH), a biopharmaceutical company focused on utilizing its proprietary cannabinoid platform to develop and commercialize novel therapeutics, announced that the Company will report its financial results for the quarter ended December 31, 2018, later this month.

In anticipation of this news, the Company's shares enjoyed a 1.55% boost to Wednesday's trading, with shares trading at $149.81 per share late in the afternoon.